Biota Pharmaceuticals, Inc. Announces Upcoming Events
April 29 2014 - 6:00AM
Management to Host Conference Call to
Review Q3 Financial Results Management to Present
at Deutsche Bank 39th Annual Health Care Conference
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the
"Company") announced today that management will host a conference
call on Tuesday, May 6, 2014 at 4:30 p.m. EDT to review the
Company's third quarter financial results and provide an update on
recent corporate developments. The Company will issue a press
release summarizing its financial results on the same day, prior to
the conference call.
To access the conference call, please dial (877) 312-5422
(domestic) or (253) 237-1122 (international). Additionally, a live
audio webcast of the call and the archived webcast will be
available in the Investors section of the Biota website at
http://www.biotapharma.com.
The Company also announced that its President and Chief
Executive Officer, Russell H. Plumb, will present an update on the
company at the Deutsche Bank 39th Annual Health Care Conference on
Thursday, May 8th at 2:10 pm at the Intercontinental Hotel in
Boston.
The presentation will be webcast live and may be accessed
through the Investor Relations' Events and Presentations section on
Biota's website at www.biotapharma.com. Please go to the website at
least 15 minutes prior to the event to register, download and
install any necessary audio/video software. An archived replay will
also be available for 90 days following the live presentation.
About Biota
Biota Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the discovery and development of products to prevent and
treat serious and potentially life-threatening infectious
diseases. The Company currently has two Phase 2 clinical-stage
product candidates: laninamivir octanoate, which the Company is
developing for the treatment of influenza A and B infections in the
United States through a contract with the U.S. Office of Biomedical
Advanced Research and Development Authority (BARDA) intended to
provide up to $231 million in financial support to complete its
clinical development; and vapendavir, a potent, oral broad spectrum
capsid inhibitor of enteroviruses, including human rhinovirus. In
addition to these clinical-stage development programs, the Company
has preclinical programs focused on developing treatments for
respiratory syncytial virus. For additional information about the
Company, please visit www.biotapharma.com.
CONTACT: Russell H. Plumb
Chief Executive Officer
(678) 221-3351
r.plumb@biotapharma.com
Lee M. Stern
The Trout Group
(646) 378-2922
lstern@troutgroup.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024